Core Viewpoint - Aptose Biosciences has initiated dosing for the first patients in the TUSCANY Phase 1/2 study, evaluating the triplet therapy of tuspetinib (TUS), venetoclax (VEN), and azacitidine (AZA) for newly diagnosed acute myeloid leukemia (AML) patients [1][2][3] Group 1: Study Details - The TUSCANY Phase 1/2 trial aims to establish an improved frontline therapy for newly diagnosed AML patients, focusing on safety, durability, and broad activity across diverse AML populations [2][4] - The trial will test various doses and schedules of TUS in combination with standard doses of azacitidine and venetoclax, with TUS starting at 40mg once daily in 28-day cycles [4] - Enrollment is expected to include 18-24 patients by mid to late 2025 across multiple U.S. sites [4] Group 2: Drug Efficacy and Safety - Previous APTIVATE trials indicated that TUS as a single agent and in combination with VEN showed favorable safety and broad activity in relapsed or refractory AML populations, including those with adverse mutations [2][3] - The triplet therapy is anticipated to deliver high response rates and longer survival for newly diagnosed AML patients while minimizing toxicities associated with other treatments [3] Group 3: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [6] - The lead clinical-stage oral kinase inhibitor, tuspetinib, has shown promise as both a monotherapy and in combination therapy for AML [6]

SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that the Nasdaq Hearings Panel (“Panel”) has granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Stock Market. On or before March 31, 2025, the Compan ...

Peer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs survival in multiple AML models resistant to other drugs Findings suggest TUS will demonstrate broad antileukemic activity across AML patients TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling SAN DIEGO and TORONTO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS ...

Core Viewpoint - Aptose Biosciences Inc. has successfully closed a public offering, raising $8 million through the sale of 40 million common shares at $0.20 each, along with warrants for an additional 20 million shares [1]. Group 1: Offering Details - The public offering included 40,000,000 common shares priced at $0.20 per share and warrants to purchase up to 20,000,000 common shares at an exercise price of $0.25 per share, which are exercisable immediately and will expire in five years [1]. - The offering was conducted by A.G.P./Alliance Global Partners as the sole placement agent [2]. - The gross proceeds from the offering amounted to $8 million before deducting fees and expenses [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes [1]. Group 3: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [5]. - The company's lead product, tuspetinib (TUS), is an oral kinase inhibitor that has shown efficacy as both a monotherapy and in combination therapy for patients with relapsed or refractory acute myeloid leukemia (AML) [5].

SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the pricing of its "reasonable best efforts" public offering with participation from the CEO and existing and new healthcare focused investors for the purchase and sale of up to 40,000,000 shares of common stock and warrants to ...

Core Insights - The TUSCANY study has been initiated to evaluate the combination of tuspetinib (TUS), venetoclax (VEN), and azacitidine (AZA) for newly diagnosed acute myeloid leukemia (AML) patients [1][2] - Tuspetinib is positioned as a frontline therapy for AML, particularly for patients who are ineligible for intensive chemotherapy, and has shown favorable safety and broad clinical activity [2][3] - The trial aims to enroll 18-24 patients across 12 clinical sites in the U.S. by mid to late 2025, with a focus on various dosing schedules of TUS [4] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for hematologic malignancies, with a pipeline that includes tuspetinib and luxeptinib [6] - Tuspetinib is an oral kinase inhibitor that targets multiple kinases and has demonstrated efficacy both as a monotherapy and in combination therapy for relapsed or refractory AML [6] - The company aims to address unmet medical needs in oncology, particularly in hematology, by enhancing the efficacy of existing therapies without overlapping toxicities [6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporatio ...

Financial Performance - Aptose reported a net loss of $6.95 million for Q3 2024, a decrease of $4.5 million compared to a net loss of $11.45 million in Q3 2023[9]. - Research and development expenses for Q3 2024 were $4.7 million, down from $8.3 million in Q3 2023, reflecting a decrease of $3.6 million[11]. - Total cash and cash equivalents as of September 30, 2024, were $8 million, providing sufficient resources to fund operations through January 2025[10]. - The accumulated deficit as of September 30, 2024, was $539.4 million, compared to $515.5 million at the end of 2023[10]. Clinical Development - Tuspetinib demonstrated broad clinical activity in AML patients during the APTIVATE trial, achieving responses in patients with diverse mutation profiles, including those with adverse genetics[3]. - The company plans to initiate dosing of the TUS+VEN+AZA triplet therapy in newly diagnosed AML patients in Q4 2024[7]. - Program costs for tuspetinib were $4.1 million for Q3 2024, down from $5.8 million in Q3 2023, primarily due to reduced clinical trial activity[12]. - Aptose is negotiating a new co-development collaboration agreement with Hanmi to accelerate the clinical development of tuspetinib[3]. - The company is focused on clinical development plans and the therapeutic potential of tuspetinib[15]. - The progress of clinical trials is a key factor influencing future performance[16]. - The company is exploring partnerships to enhance its clinical development efforts[16]. Compliance and Regulatory Issues - The company is addressing compliance issues with Nasdaq regarding stockholders' equity and minimum bid price requirements[6]. - The company is working on a compliance plan to regain Nasdaq compliance[15]. - There are risks associated with early-stage drug development, including demonstrating efficacy and regulatory approval processes[16]. Capital and Funding - The company is actively seeking capital to fund its research and operations[16]. - The company received a $10 million loan from Hanmi Pharmaceutical to support the development of tuspetinib, convertible into milestone obligations under a future collaboration agreement[3]. Forward-Looking Statements - The company does not intend to update forward-looking statements unless required by law[17]. - Investors are cautioned that forward-looking statements are not guarantees of future performance[17]. Market Conditions - There are uncertainties related to market and economic conditions that could impact results[16]. - The company aims to attract and retain key personnel for its operations[16].

SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months ended September 30, 2024, and provided a corporate update. "Triple drug therapies (triplets) that build on the standard of care in AML have yielded higher response rates yet are limited to ...

Core Viewpoint - Aptose Biosciences Inc. held a special meeting of shareholders on September 5, 2024, where key proposals regarding the issuance of common shares and potential adjournments were approved by the requisite number of votes [1]. Proposal Summary - Proposal No. 1: Approval of the issuance of common shares underlying certain warrants was passed with 3,969,105 votes in favor, representing 93.34% of the votes cast [3]. - Proposal No. 2: Approval for one or more adjournments of the meeting was also passed, with 97.05% of votes in favor [3]. Voting Results - A total of 6,052,460 common shares were voted, accounting for 33.42% of the issued and outstanding shares [1][3]. - The breakdown of votes for Proposal No. 1 included 3,969,105 votes for, 267,013 against, and 16,342 withheld/abstained [3]. - The total shares issued and outstanding were reported as 18,109,393, with 1,800,000 shares held by insiders excluded from the voting results [3]. Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [4]. - The lead compound, tuspetinib, is an oral kinase inhibitor targeting acute myeloid leukemia (AML) and is being developed for both monotherapy and combination therapy [4].